Associated Papers
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones E et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2024
Select a paper to view details